Legal Entity Novartis Pharma AG provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis Group companies employ approximately 126,000 associates (2017) and operate in more than 140 countries around the world. The Novartis strategy is to deliver better outcomes for patients through science-based innovation. Novartis is actively contributing to a number of IMI projects that may be of relevance for imSAVAR including IMI Call 14 Topic 2: Non-invasive clinical molecular imaging of immune cells.
Role within Project
- Consortium management; industry partner coordinator
- Preclinical and clinical safety assessment experience in therapeutic modes of action including CARTs/CD3xbispecific Abs/Checkpoint inhibitor Abs +/- LMW immunomodulators; in vivo and in vitro model development
- Preclinical and clinical safety assessment experience in therapeutic modulators of Treg cells, in particular recombinant human IL2; in vivo animal model development
- Molecular and cellular immune profiling assays and computational biology analyses